59.91
price up icon0.32%   0.19
after-market Handel nachbörslich: 60.05 0.14 +0.23%
loading

Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten

pulisher
12:37 PM

Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus

12:37 PM
pulisher
12:17 PM

Is Kymera Therapeutics Inc. stock supported by innovation pipeline2025 Dividend Review & Real-Time Market Trend Scan - newser.com

12:17 PM
pulisher
Nov 04, 2025

Kymera Therapeutics Reports Q3 2025 Financial Results - TipRanks

Nov 04, 2025
pulisher
Nov 04, 2025

Kymera Therapeutics’ Earnings Call Highlights Growth and Challenges - TipRanks

Nov 04, 2025
pulisher
Nov 04, 2025

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Cullinan Management (CGEM) and Idexx Laboratories (IDXX) - The Globe and Mail

Nov 04, 2025
pulisher
Nov 04, 2025

Kymera outlines mid-2027 topline readout for KT-621 Phase IIb study as pipeline advances and Gilead partnership grows - MSN

Nov 04, 2025
pulisher
Nov 04, 2025

Transcript : Kymera Therapeutics, Inc., Q3 2025 Earnings Call, Nov 04, 2025 - MarketScreener

Nov 04, 2025
pulisher
Nov 04, 2025

Kymera Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat

Nov 04, 2025
pulisher
Nov 04, 2025

Oppenheimer raises Kymera Therapeutics stock price target ahead of Phase 1b readout - Investing.com Canada

Nov 04, 2025
pulisher
Nov 04, 2025

Earnings call transcript: Kymera Therapeutics Q3 2025 misses EPS expectations - Investing.com Philippines

Nov 04, 2025
pulisher
Nov 04, 2025

Kymera Q3 2025 slides reveal strong cash position despite earnings miss - Investing.com

Nov 04, 2025
pulisher
Nov 04, 2025

Kymera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener

Nov 04, 2025
pulisher
Nov 04, 2025

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Nov 04, 2025
pulisher
Nov 04, 2025

Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update - Investing News Network

Nov 04, 2025
pulisher
Nov 04, 2025

Earnings Flash (KYMR) Kymera Posts Q3 Loss $0.94 a Share, vs. FactSet Est of $0.68 Loss - MarketScreener

Nov 04, 2025
pulisher
Nov 04, 2025

Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q3 Revenue $2.8M, vs. FactSet Est of $23.3M - MarketScreener

Nov 04, 2025
pulisher
Nov 04, 2025

Kymera Therapeutics Inc Q3 2025 Earnings: EPS of -$0.94 Misses E - GuruFocus

Nov 04, 2025
pulisher
Nov 04, 2025

Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated by Analysts at Guggenheim - MarketBeat

Nov 04, 2025
pulisher
Nov 04, 2025

Kymera Therapeutics (NASDAQ: KYMR) completes AD Phase 1b dosing, starts Phase 2b trial - Stock Titan

Nov 04, 2025
pulisher
Nov 04, 2025

Kymera Therapeutics Q3 2025 Earnings Preview - MSN

Nov 04, 2025
pulisher
Nov 03, 2025

Pattern recognition hints at Kymera Therapeutics Inc. upsideJuly 2025 Opening Moves & Expert Curated Trade Setups - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 - Investing News Network

Nov 03, 2025
pulisher
Nov 03, 2025

Guggenheim Assumes Buy Rating for Kymera Therapeutics (KYMR) | K - GuruFocus

Nov 03, 2025
pulisher
Nov 03, 2025

Kymera Therapeutics Inc (KYMR) Q3 2025 Earnings Report Preview: What to Look For - GuruFocus

Nov 03, 2025
pulisher
Nov 03, 2025

How to read the order book for Kymera Therapeutics Inc.Portfolio Growth Summary & Consistent Profit Focused Trading Strategies - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Kymera Therapeutics to Participate in Upcoming November Investor Conferences - The Manila Times

Nov 03, 2025
pulisher
Nov 03, 2025

Guggenheim assumes coverage on Kymera stock with Buy rating, $90 target - Investing.com Canada

Nov 03, 2025
pulisher
Nov 03, 2025

Kymera Therapeutics (NASDAQ: KYMR) to join 5 November investor conferences; webcasts - Stock Titan

Nov 03, 2025
pulisher
Nov 03, 2025

How analysts rate Kymera Therapeutics Inc. stock today2025 Year in Review & Stock Portfolio Risk Control - newser.com

Nov 03, 2025
pulisher
Nov 02, 2025

What valuation multiples suggest for Kymera Therapeutics Inc. stock2025 Macro Impact & Weekly Chart Analysis and Guides - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

AlphaQuest LLC Acquires New Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Nov 02, 2025
pulisher
Nov 01, 2025

34,797 Shares in Kymera Therapeutics, Inc. $KYMR Bought by Moody Aldrich Partners LLC - MarketBeat

Nov 01, 2025
pulisher
Nov 01, 2025

Is Kymera Therapeutics Inc. stock attractive for ETFsWeekly Stock Report & Weekly Breakout Opportunity Watchlist - newser.com

Nov 01, 2025
pulisher
Nov 01, 2025

Jennison Associates LLC Acquires 272,739 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat

Nov 01, 2025
pulisher
Oct 31, 2025

Kymera Therapeutics Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView

Oct 31, 2025
pulisher
Oct 30, 2025

Kymera Therapeutics (NASDAQ:KYMR) CEO Sells $1,829,700.00 in Stock - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

How hedge fund analytics apply to Kymera Therapeutics Inc. stockJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com

Oct 30, 2025
pulisher
Oct 29, 2025

Is Kymera Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Pullbacks & AI Forecasted Entry and Exit Points - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Kymera Therapeutics Insider Sold Shares Worth $1,829,737, According to a Recent SEC Filing - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

KYMR insider trade: CEO option exercise and matching share sales - Stock Titan

Oct 29, 2025
pulisher
Oct 29, 2025

Kymera Therapeutics (KYMR): Assessing Valuation Following Promising Preclinical Data for KT-579 in Autoimmune Diseases - Yahoo Finance

Oct 29, 2025
pulisher
Oct 28, 2025

How Investors Are Reacting To Kymera Therapeutics (KYMR) Preclinical Data on Oral IRF5 Degrader in Lupus and RA - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Is Kymera Therapeutics Inc. stock undervalued vs historical averagesJuly 2025 Earnings & Low Volatility Stock Recommendations - fcp.pa.gov.br

Oct 28, 2025
pulisher
Oct 28, 2025

Kymera Therapeutics to Announce Q3 2025 Financial Results and Host Video Conference on November 4, 2025 - Quiver Quantitative

Oct 28, 2025
pulisher
Oct 28, 2025

Kymera Therapeutics (NASDAQ: KYMR) to report third quarter 2025; webcast at 8:30 a.m. ET - Stock Titan

Oct 28, 2025
pulisher
Oct 28, 2025

What technical charts say about Kymera Therapeutics Inc. stockJuly 2025 Summary & Community Verified Trade Signals - Fundação Cultural do Pará

Oct 28, 2025
$37.84
price up icon 1.45%
$28.76
price up icon 0.17%
$102.92
price up icon 1.33%
$104.83
price up icon 0.84%
biotechnology ONC
$309.19
price down icon 0.86%
$182.77
price down icon 1.86%
Kapitalisierung:     |  Volumen (24h):